Every few years, a corner of the alternatives market that used to be a conversation-starter at conferences turns into something advisors are actually asked about. Litigation finance is having that moment right now. The idea itself isn’t new — funding a lawsuit in exchange for a share of the eventual award has existed in some form for decades — but the amount of institutional money flowing into it, and the way it’s being packaged for investors, has changed enough that it’s worth a fresh look.
The basic mechanics are simple even if the underwriting is not. A funder puts up capital to cover legal costs for a plaintiff or a law firm pursuing a claim, and in exchange receives a multiple of that capital, or a percentage of the recovery, if the case succeeds. If the case fails, the funder typically loses the investment entirely — there’s no collateral to fall back on the way there would be with a defaulted loan. That binary, event-driven payoff structure is exactly what makes the asset class attractive to allocators looking for something that doesn’t move with stocks or bonds. A jury verdict doesn’t care what the Fed did last week.
The Market Has Split Into Two Very Different Businesses
What’s changed in the last year or two is that litigation finance has effectively split into two distinct strategies with very different risk profiles. The first is single-case funding — betting on the outcome of one specific commercial dispute, often targeting returns north of 30% but with a real chance of losing everything. The second, and the faster-growing piece, is portfolio lending directly to law firms, which behaves much more like a private credit instrument. Aperture Investors illustrated this shift clearly in August, when it announced an expansion of its litigation finance platform to as much as $1 billion in capacity, structured almost entirely as loans to plaintiffs’ law firms rather than funding of individual cases.
That distinction matters more than it sounds like it should. A loan to a law firm with a diversified book of dozens or hundreds of active matters spreads out the binary risk of any single case across a portfolio, and the firm itself often has other assets and cash flow backing the loan. A bet on one case has none of that cushioning. Litigation finance portfolio manager Luke Darkow put it plainly in describing Aperture’s approach: the firm is deliberately treating the strategy “through a private credit lens,” which is a meaningfully more conservative posture than the industry’s earlier reputation for chasing blockbuster verdicts.
Growth Has Attracted Both New Capital and Distressed Sellers
Sizing the market depends heavily on which research firm you ask, but the direction is consistent. Estimates put the U.S. litigation finance market at roughly $22 to $26 billion in committed capital for 2026, with double-digit annual growth projected out to the early 2030s, according to figures compiled by Research Nester. Pension funds, sovereign wealth funds, and hedge funds have all become more active participants, drawn by the low correlation to public markets and, candidly, by return targets that are hard to find elsewhere in credit right now.
But growth hasn’t been uniformly smooth. Earlier this year, a wave of underperforming cases and slower-than-expected settlements pushed some existing litigation finance positions into distress, and opportunistic buyers moved in. Bloomberg Law reported that distressed-debt specialists including Davidson Kempner Capital Management were buying legal claims at valuations as low as 10 cents on the dollar, in some cases taking on the position for free in exchange for a small payment to the original funder if the case eventually wins. That kind of secondary market activity is actually a healthy sign for the asset class over the long run — it means capital can exit a bad bet before maturity instead of being stuck — but it’s also a reminder that the loss scenarios in this space are real and can show up in bunches rather than gradually.
How Individual Investors Are Actually Getting Exposure
For most retail investors, direct access to litigation finance still isn’t practical. Minimum investments on institutional platforms commonly run into the hundreds of thousands of dollars, and the underwriting expertise required to evaluate a legal claim is nothing like evaluating a bond or a stock. What has changed is that a small number of platforms now offer fractional or lower-minimum access to diversified pools of cases rather than single-case bets, spreading the binary risk the way a fund would. That structure is a meaningfully different proposition than writing a check against one lawsuit, and it’s the version of this asset class that’s realistic for most advisors to even discuss with clients.
The tax treatment is also worth flagging before anyone gets excited about the headline return figures. Gains from litigation finance are generally treated as ordinary income rather than capital gains in most structures, which changes the after-tax math considerably for investors in higher brackets. That’s a detail that gets lost in the marketing material for this asset class more often than it should.
Where It Fits, and Where It Doesn't
The honest pitch for litigation finance is narrow: it’s a small satellite allocation for investors who already have their core stock and bond exposure covered and are looking for genuine diversification rather than another correlated risk asset wearing a different label. It is not a bond substitute, despite some of the portfolio-lending structures resembling private credit on paper. The underlying collateral, when it exists at all, is a legal claim whose value depends on a judge, a jury, or a settlement negotiation — not a cash flow stream or a hard asset.
It’s also not a strategy where past returns tell you much about future ones. Litigation outcomes don’t cluster the way credit defaults do during a recession; a portfolio of cases can look fine for years and then take a hit from a handful of adverse rulings that have nothing to do with the broader economy. For investors and advisors who are comfortable with that kind of idiosyncratic risk and are sizing the position accordingly — most practitioners suggest keeping any single alternative sleeve like this well under 5% of a portfolio — litigation finance offers something that’s genuinely hard to find elsewhere: a return stream driven by the legal system rather than interest rates or corporate earnings.
The Insurance Layer Is Changing Who Can Get Involved
One development that’s easy to miss is the growing role of litigation insurance as a companion product to funding itself. Insurers now underwrite policies that protect against adverse cost awards or guarantee a minimum recovery in certain matters, and that layer is starting to reshape the risk that funders themselves are taking on. A funder backing a case that also carries an insurance policy against the worst outcomes is taking a meaningfully different risk than one funding a bare, uninsured claim — closer, in practice, to structured credit than to a pure legal wager. That evolution is part of why some allocators who wouldn’t have touched litigation finance a few years ago are willing to look at it now, provided the specific structure includes that kind of downside protection.
Due Diligence Looks Nothing Like Underwriting a Bond
For anyone evaluating a fund or platform in this space, the diligence questions are almost entirely different from what applies elsewhere in fixed income or credit. Case selection criteria, the experience and track record of the underwriting team, the average time to resolution across the portfolio, and how concentrated the book is by case type and jurisdiction all matter more than anything resembling a credit rating, because there isn’t one. A portfolio heavily weighted toward a single practice area — mass tort claims, for instance, or a specific type of commercial dispute — carries a different risk than one spread across case types, plaintiff profiles, and courts, even if both are marketed under the same litigation finance label. Investors who can’t get clear answers to those questions from a platform or fund sponsor should treat that opacity itself as a warning sign, regardless of how attractive the headline return target looks.
For everyone else who decides this isn’t the right fit, it’s still worth understanding as a growing and increasingly institutionalized part of the alternatives landscape, if only because it’s likely to keep showing up in conversations about portfolio diversification even for investors who never put a dollar into it themselves.
